Related Experiment Video
Updated: Jun 7, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
A fourth dimension in decision making in hepatology
1Gastroenterology and Liver Units, Deparent of Medicine, Hadassah Hebrew University Medical Center; Jerusalem, Israel.
Insights
The (13)C methacetin breath test (MBT) offers a rapid, non-invasive method for assessing liver function. This point-of-care tool aids clinical decisions in managing acute and chronic liver disease patients.
Area of Science:
- Hepatology
- Medical Diagnostics
- Biochemistry
Background:
- Current liver function tests (biopsy, blood tests) often lack sensitivity for timely patient follow-up.
- Accurate liver function assessment is crucial for prognosis and treatment decisions in liver disease.
- Existing methods provide only indirect evidence of hepatic impairment.
Purpose of the Study:
- To review the utility of the point-of-care (13)C methacetin breath test (MBT) for assessing hepatic functional reserve.
- To highlight the MBT's role in clinical decision-making for liver disease management.
- To present treatment algorithms informed by MBT results.
Main Methods:
- Utilizes the liver-specific metabolism of (13)C-labeled methacetin.
- Employs molecular correlation spectroscopy to measure exhaled (13)C.
- Focuses on a rapid, non-invasive, point-of-care breath test approach.
Main Results:
- The (13)C MBT accurately assesses liver metabolic function.
- Demonstrates the test's ability to evaluate hepatic functional reserve in acute and chronic liver disease.
- Provides a sensitive measure for patient follow-up and treatment guidance.
Conclusions:
- The (13)C MBT is a valuable tool for bedside decision-making in clinical hepatology.
- Enables precise assessment of liver function, aiding in prognosis and treatment planning.
- Facilitates timely interventions for patients with liver disorders.
Abstract:
Today, the assessment of liver function in patients suffering from acute or chronic liver disease is based on liver biopsy and blood tests including synthetic function, liver enzymes and viral load, most of which provide only circumstantial evidence as to the degree of hepatic impairment. Most of these tests lack the degree of sensitivity to be useful for follow-up of these patients at the frequency that is needed for decision making in clinical hepatology. Accurate assessment of liver function is essential to determine both short- and long-term prognosis, and for making decisions about liver and non-liver surgery, TIPS, chemoembolization or radiofrequency ablation in patients with chronic liver disease. Liver function tests can serve as the basis for accurate decision-making regarding the need for liver transplantation in the setting of acute failure or in patients with chronic liver disease. The liver metabolic breath test relies on measuring exhaled (13) C tagged methacetin, which is metabolized only by the liver. Measuring this liver-specific substrate by means of molecular correlation spectroscopy is a rapid, non-invasive method for assessing liver function at the point-of-care. The (13) C methacetin breath test (MBT) is a powerful tool to aid clinical hepatologists in bedside decision-making. Our recent findings regarding the ability of point-of-care (13) C MBT to assess the hepatic functional reserve in patients with acute and chronic liver disease are reviewed along with suggested treatment algorithms for common liver disorders.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Dimensions of Health and Illness
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Decision Making
Automatic decision-making is fast, intuitive, and relies on gut feelings...

